Publications

library

Publications

The scientific background of Modiblast therapy has been described in numerous peer-reviewed publications. Over the years, our Helga Schmetzer has authored a total of more than 200 papers, posters, congress contributions and review articles, of which more than 30 focus on the immunobiology of leukemia. A selection of her papers is listed below.

Most relevant publications for the Modiblast Technology

  1. M. Schmetzer et al., Int. J. Mol. Sci. 2024, 25(24), 13469. In Vivo Induction of Leukemia-Specific Adaptive and Innate Immune Cells by Treatment of AML-Diseased Rats and Therapy-Refractory AML Patients with Blast Modulating Response Modifiers.
  2. M. Schmetzer et al., Leukemia 21(6): 1338-1341 (2007). Quantification of ex vivo generated dendritic cells (DC) and leukemia-derived DC contributes to estimate the quality of DC, to detect optimal DC-generating methods or to optimize DC-mediated T-cell.
  3. Kremser et al., J. Immunother. 33(2): 185-199 (2010). Dendritic cells can be success­fully generated from leukemic blasts in individual patients with AML or MDS.
  4. Reuther et al., Clin. Exp. Med. 13(1): 29-48 (2013). In vitro-induced response patterns of anti-leukemic T cells: characterization by spectratyping and immunophenotyping.
  5. Schick et al., J. Immunother. 36(4): 223-237 (2013). Anti-leukemic T-cell responses can be predicted by the composition of specific regulatory T-cell subpopulations.
  6. Vogt et al., J. Immunother. 37(6): 331-347 (2014). Profiles of activation, differentiation-markers, or b-integrins on T cells contribute to predict T cells’ anti-leukemic responses after stimulation with leukemia-derived dendritic cells.
  7. H.-J. Kolb et al., Leukemia Suppl. 3(1): S16-S17 (2014). Mechanisms of graft-versus-leukemia effects after allogeneic stem cell transplantation: effects on the leukemia stem cell?
  8. L. Boeck et al., J. Immunother. 40(6): 224-248 (2017). Significance of Frequencies, Compositions, and/or Anti-leukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL.
  9. Hirn-Lopez et al., J. Immunother. 42(5): 143-161 (2019). Role of Interferon (IFN)α in “Cocktails” for the Generation of (Leukemia-derived) Dendritic Cells (DCleu) From Blasts in Blood From Patients (pts) With Acute Myeloid Leukemia (AML) and the Induction of Anti-Leukemic Reactions.
  10. C. Amberger et al., Int. J. Mol. Sci. 20(18): 4590 (2019). PGE1-Containing Protocols Generate Mature (Leukemia-Derived) Dendritic Cells Directly from Leukemic Whole Blood.
  11. Ansprenger et al., Clin. Immunology 217: 108467 (2020). Potential of immunotherapies in the mediation of antileukemic responses for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) – With a focus on Dendritic cells of leukemic origin (DCleu).
  12. Eiz-Vesper and H. M. Schmetzer, Transfus. Med. Hemother. 47(6): 429-431 (2020). Antigen-Presenting Cells: Potential of Proven und New Players in Immune Therapies.
  13. C. Amberger and H. M. Schmetzer, Transfus. Med. Hemother. 47(6): 432-443 (2020). Dendritic Cells of Leukemic Origin: Specialized Antigen-Presenting Cells as Potential Treatment Tools for Patients with Myeloid Leukemia.
  14. K. Klauer et al., Transfus. Med. Hemother. 49(1): 44-61 (2022). Interferon Gamma Secretion of Adaptive and Innate Immune Cells as a Parameter to Describe Leukaemia-Derived Dendritic Cell-Mediated Immune Responses in Acute Myeloid Leukaemia in vitro.
  15. Freudenreich et al., Transfus. Med. Hemother. 45(2): 104-118 (2020). In Vitro Generated Dendritic Cells of Leukemic Origin Predict Response to Allogeneic Stem Cell Transplantation in Patients With AML and MDS.